Deep Analysis of Impact of COVID-19 on “CRISPR & Cas Genes Market 2020-2027” Growth Worldwide….
The global clustered
regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated
(Cas) genes market size
is expected to reach USD 4.88 billion by
2027, expanding at a CAGR of 16.6%
from 2020 to 2027, according to a new report by Grand View Research, Inc.
Rise in the adoption of CRISPR technology in epigenetics, therapeutics, human
germline editing, plant genome editing, and other fields of biotechnology is
expected to drive the market.
Biopharmaceutical innovators are at the
forefront of the human response to the coronavirus pandemic. A significant
number of major biotech firms are in the midst of a race to investigate the
Sars-Cov-2 genome and prepare a viable vaccine for the same. As compared to the
speed of response to SARS/MERs etc, the biotech entities are investigating
SARs-Cov-2 at an unprecedented rate and a considerable amount of funds are
being put into the R&D. With multiple candidates in trial, the public and
private sectors are anticipated to work in unison for the foreseeable period,
until a vaccine is developed for Covid-19. The report will account for Covid19
as a key market contributor.
Presence of a large number of service
providers that provide knockout, knock-in, gene repression, gene activation,
and other cell line engineering services propel the growth of cell line
engineering services. In biomedical applications, genome engineering held the
largest revenue share in 2020. Adoption of gene editing techniques for human-
and non-human-based genomic engineering is one of the key factors that drive
the segment.
The molecular scissor can facilitate
the detection of viruses, allowing the development of cost-effective, robust,
and rapid point-of-care diagnostics. It allows the detection of viruses at a
level of molecular concentration that researchers rarely assess. Sherlock
Bioscience estimated that a CRISPR-powered diagnostic test would be available
in the future at a reasonable price. In recent times, the most important
innovation has been the development of a test for COVID-19.
To Request Sample Copy of this report, click the link:
In March 2020, Mesa Biotech announced
FDA authorization for its Accula device, a hand-held COVID-19 diagnostic test.
Similarly, in April 2020, CSIR lab announced the development of a paper-strip
test for Covid-19 that uses CRISPR-Cas9 to target and identifies the genomic
sequences of the virus. Unlike the PCR tests, this test is available at a very
low price, USD 6.59 (INR 1 = USD 0.013). Therefore, such initiatives are
expected to encourage other players to leverage this crisis and launch novel
products.
CRISPR & Cas Genes Market Report
Highlights
·
The product segment is
anticipated to dominate the market throughout the forecast period. This is
attributed to the presence of enhanced individual products that can serve
multiple purposes including genome engineering, specific genome cleavage using
gRNAs, easy gene knockouts, along with reduced off-target cutting, and
increased specificity
·
Cell line engineering services
accounted for the largest market share in 2020. The development of this
technology has simplified the genome engineering process to a large extent
·
In biomedical applications,
genome engineering held the largest revenue share in 2020 as a result of an
increase in the adoption of genome editing techniques for modifications in
germline and therapeutics development
·
Recent advancements in
CRISPR/Cas genome editing allow targeted modification in crops, thereby
promising crop improvement and revenue generation in the market
·
A significant number of
research studies carried out to develop disease-specific novel therapies and
presence of a huge clinical pipeline that integrates the application of this
gene-editing technology are expected to boost revenue generation for the
biotechnology and pharmaceutical companies segment
·
Asia Pacific is anticipated to
witness the fastest growth over the forecast period. China holds a significant
position in the CRISPR market and is increasingly exploring genome-editing for the
development of medicines. The country has launched several CRISPER-based
clinical trials, especially for cancer treatment.
The
global clustered regularly interspaced short palindromic repeats (CRISPR) and
CRISPR-associated (Cas) genes market size was valued at USD 1.42 billion in
2020 and is expected to grow at a compound annual growth rate (CAGR) of 16.6%
from 2020 to 2027. Technological advancements in the genome editing platform
are expected to drive the market at a significant rate. Recently, two new
versions of the Cas9 protein: eSpCas9 and SpCas9-HF have been engineered to
minimize off-target editing activity without the requirement for two sgRNAs. In
addition, accelerated research for novel enzymes, protein and gRNA engineering,
and off-target detection methods is expected to introduce novel techniques.
Moreover, introduction of anti-CRISPR proteins will provide new avenues for the
market as these proteins can potentially enhance the accuracy of this
technology.
Have any Query? Ask our Experts:
Researchers
at UC Berkeley and UC San Francisco have developed an anti-CRISPR protein
called AcrIIA4. This protein reduces the off-target effects of this technology
by four-folds, without reducing the desired on-target gene-editing. A rapid
succession of the research papers pertaining to the use of anti-CRISPR proteins
for silencing the effect of Cas genes is expected to drive the usage of this
technology.
About Grand View
Research
Grand View Research,
Inc. is a U.S. based market research and consulting company, registered in the
State of California and headquartered in San Francisco. The company provides
syndicated research reports, customized research reports, and consulting services.
To help clients make informed business decisions, we offer market intelligence
studies ensuring relevant and fact-based research across a range of industries,
from technology to chemicals, materials and healthcare.
Comments
Post a Comment